Affiliation:
1. OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Plácido da Costa, 4200-450 Porto,Portugal
Abstract
:
Antimalarial drugs from different classes have demonstrated anticancer effects in different types of cancer
cells, but their complete mode of action in cancer remains unknown. Recently, several studies reported the important
role of palmitoyl-protein thioesterase 1 (PPT1), a lysosomal enzyme, as the molecular target of chloroquine and its
derivates in cancer. It was also found that PPT1 is overexpressed in different types of cancer, such as breast, colon,
etc. Our group has found a synergistic interaction between antimalarial drugs, such as mefloquine, artesunate and
chloroquine and antineoplastic drugs in breast cancer cells, but the mechanism of action was not determined. Here,
we describe the importance of autophagy and lysosomal inhibitors in tumorigenesis and hypothesize that other antimalarial
agents besides chloroquine could also interact with PPT1 and inhibit the mechanistic target of rapamycin
(mTOR) signalling, an important pathway in cancer progression. We believe that PPT1 inhibition results in changes
in the lysosomal metabolism that result in less accumulation of antineoplastic drugs in lysosomes, which increases
the bioavailability of the antineoplastic agents. Taken together, these mechanisms help to explain the synergism of
antimalarial and antineoplastic agents in cancer cells.
Funder
Fundação para a Ciência e a Tecnologia (FCT) National Funds
Publisher
Bentham Science Publishers Ltd.
Subject
Clinical Biochemistry,Pharmacology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献